Synopsis
The pharmaceutical industry, and the central drug regulatory agency, faced a severe reputation crisis following the deaths of 70 children in Gambia due to contaminated cough syrups in 2022. A few months later, Rajeev Raghuvanshi took over as the Drug Controller General of India and is currently driving a transformational change. Can he set a high bar for product quality?
For a moment, one might mistake it for a corporate office. Shiny cars pulling over. Executives in dapper suits sauntering in. That’s how the FDA Bhawan — the headquarters of India’s apex drug regulatory agency, the Central Drug Standard Control Organisation (CDSCO) — in Delhi’s bustling ITO area always looked. The building is at the heart of every critical decision that impacts the Indian pharmaceutical industry – from launch of new drugs to
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
